Merck kick-starts PhIII cholesterol trials for its oral PCSK9; Baxter recalls 13,000+ vials of chemotherapy
Merck revealed Friday it started up its first late-stage clinical program for an oral PCSK9 inhibitor for cholesterol.
The program is currently enrolling participants in two registrational studies for MK-0616, which aims to lower LDL cholesterol. An outcomes study is also set to start this year, with plans to enroll a combined 17,000 patients between all three trials.
The registrational trials are expected to wrap up in 2025, and the outcomes study in 2029.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.